Another study examined the effects of a HER2 gene polymorphism (Ile655Val) on the pharmacodynamics of trastuzumab-induced cardiotoxicity, suggesting that the presence of the Val allele may be a risk factor for cardiotoxicity induced by trastuzumab in breast cancer patients [191, 192]. The gene discussed is ERBB2; the disease is breast cancer.